{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:19:13Z","timestamp":1794406753733,"version":"4.9.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Atopic dermatitis (<jats:sc>AD<\/jats:sc>) is a common and burdensome disease. Treatment options for pediatric and adolescent patients (&lt;\u200918\u2009years old) with moderate\u2010to\u2010severe <jats:sc>AD<\/jats:sc> are limited, and real\u2010world data on disease burden are lacking. This study examined patient\u2010reported disease burden and treatments in pediatric and adolescent patients to identify opportunities for patient benefit. Data were drawn from the Adelphi Real World Pediatric <jats:sc>AD<\/jats:sc> Disease Specific Programme (DSP), a cross\u2010sectional survey of physicians and patients &lt;\u200918\u2009years old, conducted in Europe and the United States between February\u2013June 2019. Physicians documented demographics, clinical characteristics, and treatment history. Patients and\/or their caregivers described disease burden, the degree of symptomatic bother, and quality of life (QoL). Data from 772 patients with moderate\u2013to\u2010severe <jats:sc>AD<\/jats:sc> were analyzed (pediatric; <jats:italic>n<\/jats:italic>\u2009=\u2009393, 0\u201311\u2009years, adolescent; <jats:italic>n<\/jats:italic>\u2009=\u2009379, 12\u201317\u2009years). Adolescents were more likely to be receiving a systemic corticosteroid (24% vs. 12%), phototherapy (15% vs. 6%), systemic immunosuppressant (15% vs. 6%) or a biologic treatment (5% vs. 1%) than pediatric patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Two\u2010thirds of patients had a high degree of \u201cbother\u201d from itch, and 38% reporting itch as the \u201cmost bothersome\u201d symptom. More adolescent patients reported \u201cbother\u201d related to anxiety than pediatric patients (67% vs. 49%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Adolescent patients reported a significantly higher burden of embarrassment\/self\u2010consciousness (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and <jats:sc>AD<\/jats:sc> impact on friendships (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Disease burden differed between pediatric and adolescent patients with <jats:sc>AD<\/jats:sc>. Treatment considerations for pediatric and adolescent patients with <jats:sc>AD<\/jats:sc> should take into account these factors, with future research directed toward improving the QoL in these patients.<\/jats:p>","DOI":"10.1111\/pde.15940","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T01:47:26Z","timestamp":1745200046000},"page":"523-531","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient\u2010Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate\u2010To\u2010Severe Disease: Results of a Real\u2010World, Cross\u2010Sectional Survey"],"prefix":"10.1111","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[{"name":"Department of Dermatology and Pediatrics University of California, San Diego School of Medicine and Rady Children's Hospital  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9428","authenticated-orcid":false,"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Washington  Seattle Washington, DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-3170","authenticated-orcid":false,"given":"JiaDe","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Massachusetts General Hospital  Boston Massachusetts USA"},{"name":"Department of Dermatology Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-2835","authenticated-orcid":false,"given":"Evangeline J.","family":"Pierce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-0014","authenticated-orcid":false,"given":"Amber Reck","family":"Atwater","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-6290","authenticated-orcid":false,"given":"Jenny","family":"Austin","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2171-8228","authenticated-orcid":false,"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,20]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007\u20102232"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3569"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12270"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12619"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010018\u20100001\u2010z"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20101681"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18\u20102246"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223\u2010018\u20100281\u20106"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.06.010"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102133.148.s63.1.x"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40521\u2010017\u20100140\u20106"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000527007"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000266\u20106"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2279679"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.1995.tb16953.x"},{"key":"e_1_2_13_20_1","unstructured":"EphMRA \u201cEuropean Pharmaceutical Market Research Association Code of Conduct\/AER Guidelines \u201daccessed May 20 2020 https:\/\/www.ephmra.org\/standards\/code\u2010of\u2010conduct\u2010aer\/."},{"key":"e_1_2_13_21_1","unstructured":"StataCorp \u201cStata Statistical Software: Release 17 \u201d(2021) College Station TX: StataCorp LLC."},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742\u20101241.2006.01047.x"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040462"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2010.01.004"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231159337"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.15940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:45:43Z","timestamp":1751525143000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.15940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/pde.15940"],"URL":"https:\/\/doi.org\/10.1111\/pde.15940","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,20]]},"assertion":[{"value":"2024-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}